FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012128790> ?p ?o ?g. }

• W2012128790 endingPage "820" @default.
• W2012128790 startingPage "811" @default.
• W2012128790 abstract "Summary Chronic hepatitis B infection is an important cause of liver‐related mortality in C hina. This study assessed the efficacy and safety of entecavir in a heterogeneous patient population from a ‘real‐world’ clinical practice setting in C hina. This prospective, observational cohort provides 48‐week data on 2600 patients from 50 sites in C hina who received entecavir (0.5 or 1.0 mg) and were assessed for virologic, serologic and biochemical responses. Patients were nucleos(t)ide‐naïve or ‐experienced and had compensated or decompensated liver function. At Week 48, 1545/2424 (64%) patients with compensated liver disease and 30/44 (68%) patients with decompensated liver disease achieved HBV DNA <50 IU/mL. Greater proportions of nucleos(t)ide‐naïve than nucleos(t)ide‐experienced (69% vs 53%), and adefovir‐experienced than lamivudine/telbivudine‐experienced (62% vs 52%) patients achieved this endpoint. Most patients with HBV DNA <50 IU/mL also achieved HBV DNA <12 IU/L (60%, 45% and 61% of nucleos(t)ide‐naïve, nucleos(t)ide‐experienced and decompensated patients, respectively). In patients with compensated liver disease, ALT values normalized in 1532/1792 patients (85%), and HB eAg loss and HB eAg seroconversion were observed in 17% and 15% of treatment‐naïve and 15% and 11% of treatment‐experienced patients. Entecavir was generally well tolerated. Adverse event rates were comparable between treatment‐naïve and treatment‐experienced patients with compensated liver disease, but were higher in decompensated than in compensated patients, consistent with previous reports in these patients with more advanced disease. Four patients discontinued treatment due to adverse events. In a ‘real‐world’ setting, entecavir was efficacious and well tolerated throughout 48 weeks in a heterogeneous C hinese CHB population." @default.
• W2012128790 created "2016-06-24" @default.
• W2012128790 creator A5004289768 @default.
• W2012128790 creator A5008566878 @default.
• W2012128790 creator A5014268039 @default.
• W2012128790 creator A5016396916 @default.
• W2012128790 creator A5019237114 @default.
• W2012128790 creator A5021287604 @default.
• W2012128790 creator A5034552479 @default.
• W2012128790 creator A5041341594 @default.
• W2012128790 creator A5042760155 @default.
• W2012128790 creator A5046136378 @default.
• W2012128790 creator A5047697581 @default.
• W2012128790 creator A5056241757 @default.
• W2012128790 date "2013-05-29" @default.
• W2012128790 modified "2023-10-16" @default.
• W2012128790 title "Efficacy and safety of entecavir treatment in a heterogeneous<scp>CHB</scp>population from a ‘real‐world’ clinical practice setting in<scp>C</scp>hina" @default.
• W2012128790 cites W112572118 @default.
• W2012128790 cites W1868509006 @default.
• W2012128790 cites W1906881483 @default.
• W2012128790 cites W1912024884 @default.
• W2012128790 cites W1977856241 @default.
• W2012128790 cites W1983630195 @default.
• W2012128790 cites W1985860298 @default.
• W2012128790 cites W2004054613 @default.
• W2012128790 cites W2016092083 @default.
• W2012128790 cites W2022770725 @default.
• W2012128790 cites W2027543203 @default.
• W2012128790 cites W2031317669 @default.
• W2012128790 cites W2042823917 @default.
• W2012128790 cites W2049234248 @default.
• W2012128790 cites W2051976356 @default.
• W2012128790 cites W2058376942 @default.
• W2012128790 cites W2071476028 @default.
• W2012128790 cites W2075528292 @default.
• W2012128790 cites W2088527445 @default.
• W2012128790 cites W2089145440 @default.
• W2012128790 cites W2089727509 @default.
• W2012128790 cites W2093208686 @default.
• W2012128790 cites W2108147025 @default.
• W2012128790 cites W2119888523 @default.
• W2012128790 cites W2126563189 @default.
• W2012128790 cites W2128922663 @default.
• W2012128790 cites W2137544368 @default.
• W2012128790 cites W2143584498 @default.
• W2012128790 cites W2154488194 @default.
• W2012128790 cites W2915810710 @default.
• W2012128790 cites W4211026375 @default.
• W2012128790 cites W4238805660 @default.
• W2012128790 doi "https://doi.org/10.1111/jvh.12115" @default.
• W2012128790 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23876210" @default.
• W2012128790 hasPublicationYear "2013" @default.
• W2012128790 type Work @default.
• W2012128790 sameAs 2012128790 @default.
• W2012128790 citedByCount "14" @default.
• W2012128790 countsByYear W20121287902015 @default.
• W2012128790 countsByYear W20121287902016 @default.
• W2012128790 countsByYear W20121287902017 @default.
• W2012128790 countsByYear W20121287902018 @default.
• W2012128790 countsByYear W20121287902019 @default.
• W2012128790 countsByYear W20121287902020 @default.
• W2012128790 crossrefType "journal-article" @default.
• W2012128790 hasAuthorship W2012128790A5004289768 @default.
• W2012128790 hasAuthorship W2012128790A5008566878 @default.
• W2012128790 hasAuthorship W2012128790A5014268039 @default.
• W2012128790 hasAuthorship W2012128790A5016396916 @default.
• W2012128790 hasAuthorship W2012128790A5019237114 @default.
• W2012128790 hasAuthorship W2012128790A5021287604 @default.
• W2012128790 hasAuthorship W2012128790A5034552479 @default.
• W2012128790 hasAuthorship W2012128790A5041341594 @default.
• W2012128790 hasAuthorship W2012128790A5042760155 @default.
• W2012128790 hasAuthorship W2012128790A5046136378 @default.
• W2012128790 hasAuthorship W2012128790A5047697581 @default.
• W2012128790 hasAuthorship W2012128790A5056241757 @default.
• W2012128790 hasConcept C126322002 @default.
• W2012128790 hasConcept C159654299 @default.
• W2012128790 hasConcept C197934379 @default.
• W2012128790 hasConcept C203014093 @default.
• W2012128790 hasConcept C2522874641 @default.
• W2012128790 hasConcept C2776175608 @default.
• W2012128790 hasConcept C2777075537 @default.
• W2012128790 hasConcept C2777382497 @default.
• W2012128790 hasConcept C2777451964 @default.
• W2012128790 hasConcept C2777869810 @default.
• W2012128790 hasConcept C2779517838 @default.
• W2012128790 hasConcept C2780593183 @default.
• W2012128790 hasConcept C2781144229 @default.
• W2012128790 hasConcept C2908647359 @default.
• W2012128790 hasConcept C2992208098 @default.
• W2012128790 hasConcept C71924100 @default.
• W2012128790 hasConcept C90924648 @default.
• W2012128790 hasConcept C99454951 @default.
• W2012128790 hasConceptScore W2012128790C126322002 @default.
• W2012128790 hasConceptScore W2012128790C159654299 @default.
• W2012128790 hasConceptScore W2012128790C197934379 @default.
• W2012128790 hasConceptScore W2012128790C203014093 @default.
• W2012128790 hasConceptScore W2012128790C2522874641 @default.
• W2012128790 hasConceptScore W2012128790C2776175608 @default.

• next